Vanguard Global Advisers
LUCD icon

Vanguard Global Advisers’s Lucid Diagnostics LUCD Stock Holding History

Vanguard Global Advisers’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.6K Hold
24,900
– – ﹤0.01% 3255
2026
Q1 		$28.6K Buy
+24,900
New +$31.7K ﹤0.01% 3208

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Vanguard Global Advisers's LUCD Position: Q2 2026 in Review

Vanguard Global Advisers held its Lucid Diagnostics (LUCD) position steady in Q2 2026 at 24,900 shares worth $26.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3255.

Vanguard Global Advisers first reported a position in LUCD in Q1 2026 and has held it in 2 quarters since. The position peaked at $28.6K in Q1 2026. 113 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Vanguard Global Advisers held 24,900 shares of Lucid Diagnostics worth $26.6K as of Q2 2026.
  • Vanguard Global Advisers left its Lucid Diagnostics share count unchanged in Q2 2026.
  • Lucid Diagnostics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3255 holding.
  • Vanguard Global Advisers first reported a position in Lucid Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Lucid Diagnostics position peaked at $28.6K in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.